Search

The OLEAF4VALUE project is an ambitious initiative funded by the European Union under the Horizon 2020 program, aimed at transforming olive leaf biomass, an underutilized resource, into high-value

Despite market contraction in 2023, strategic interest in biologics and advanced therapies remains robust, with a rebound expected by 2025.

Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2.

Similar to Sabadell Asabys Fund I, the Fund II portfolio will include companies within the fields of biopharma, medtech and digital health that provide a clear benefit for patients.

We interviewed Pedro Martínez Córdoba, Councilman for Economic Promotion at the Salamanca City Council, Silver Sponsor of the fifth edition of the Green Innovation Forum.

Simbionte has been selected to join Lanzadera, one of the leading acceleration programs in Europe. This opportunity will allow the agency to solidify its position as the top choice for Biotech SMEs

Before carrying out any investment round, it is essential to first quantify the start-up/spin-off's need for cash.

BCN HEALTH has published the study ‘Burden of Hodgkin and non-Hodgkin lymphoma in Spain over a 10-year period: Productivity losses due to premature mortality’ in the Expert Review of Pharmacoeconomics

The business delegation led by the Cluster Tecnolóxico Empresarial das Ciencias da Vida (Bioga) from 9 to 13 September, will be made up of the Galician biotech companies AMSbiopharma, AFFINImeter and

This award acknowledges the company’s groundbreaking work in microbial expression systems and its ongoing commitment to delivering cutting-edge biotechnological solutions for the global market.

Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in Spain and the USA within 21 months.

This regenerative medicine project will carry out the first clinical trial in Spain to treat burns and skin wounds with autologous bioprinted human skin substitutes.

Klinea, part of an innovation ecosystem in Advanced Therapies.

The Innovative SME publishes the experiment on video and claims that its technology would solve 25% of the CO 2 target set by the IPCC group for 2030.

The Barcelona Science Park of the University of Barcelona (UB) will host two new research centres with ties to Barcelona’s Hospital Clínic: the August Pi i Sunyer Biomedical Research Institute

Oryzon Genomics, a clinical-stage biopharmaceutical company, is advancing vafidemstat, its LSD1 inhibitor for CNS disorders, as a potential treatment for Borderline Personality Disorder (BPD). BPD is

The newly created company, based in Santiago de Compostela, has been one of the three awardees in the IMPACTO 2024 edition.

BCN HEALTH, presents three different studies about the incidence and medical costs in prostate cancer, lupus and chronic obstructive respiratory disease. The study was made between June 2016 and

Zebrafish are valuable, robust, and cost-effective models for toxicity testing in the early stages of product development.